The supposition of the mechanism of escitalopram makes a dopamine nerve activity rise by inhibiting corticotropinreleasing factor to the non-organic-pain ～A SSRI application is desirable for a non-organic-pain～ by OHKUBO Tsunemasa et al.
31高山赤十字病院紀要　第43号：p31－34（2019）
The supposition of the mechanism of escitalopram makes 
a dopamine nerve activity rise by inhibiting corticotropin-
releasing factor to the non-organic-pain
～A SSRI application is desirable for a non-organic-pain～
Tsunemasa OHKUBO１）２） 　Muich KAITO３）４） 　Toshihiro ANDO５） 　and Hideaki KATO４） 　
　
１）Gifu University Graduate School of Medicine A part-time instructor, Gifu Japan
２）Japanese Soc. of Psychosomatic Medicine A delegate, Tokyo Japan
３）Japanese Red Cross Takayama Hosp., Dept. of neuropathic internal medicine, Takayama Japan
４）Suda mental hosp., Takayama Japan
５）Japanese Red Cross Takayama Hosp., Dept. of psychological medicine, Takayama Japan
 
　These contents obtain the approval of Japanese Red Cross Takayama Hospital Ethics Committee 
and it is considering sufficiently about the ethical models such as the protection of the privacy.
　As for this publication, it should elucidate a publisher.There is not a state of the conflict of 
interests (COI).
Summary
　Although escitalopram (ESC) is no having dopamine (DA) transporter (DAT) inhibitory-action, 
having dopamine nerve (A10 nerve) stimulus operation by the ESC used basic experiment is 
reported. We supposed the mechanism that the DA increases and it supposed the mechanism that 
makes a non-organic pain disappear with ①5-HT reinforcement of the descending pain modulatory 
system, ②the opioid receptor activation with the descending pain modulatory system, ③negative 
emotion block from the amygdala and the hippocampus to the nucleus accumbens, ④5-HT1A 
receptor stimulation from the activation of the amygdala, ⑤DA-phasic activity activation.
 As a result ④ and ⑤ two items were an operation with a main restraint mechanism of a non-
organic-pain. ESC is different from other SSRIs, and we know that ESC make a DA increase at the 
VTA. We supposed amygdala that a functional depression declined by corticotropin-releasing factor 
(CRF) is improved with ④ and ③. After DA stimulate by A10 nerve, DA is undergone metabolic 
change to, and the endogenous opioid   peptide (βendorphin) is made.
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Ⅰ　Introduction
　At the life-support of the animal which 
contains a human being, it is important as for the 
feeling of pain, the pressure of the postoperative 
pain, neuropathic pain or pschosocial background 
in addition to the inflammation are merely 
influenced by more than one piece of cause. As 
for the glossodynia which is the typical affection 
of the non- organic-pain of the maxilla-facial area, 
the cause isn't clear yet.  In the ambulatory-
practice, it is one of the affections most anxiously 
in the diagnosis and at the medical treatment. 
At meals, the tongue pain often reduces and it 
often disappears but daily, it appears something 
like the inflammatory diseases. Specifically, it 
experiences a lot of examples to occur more 
often and to complain to the woman of the 
convex experience which is in the cancer age 
of them as the cancer phobia, too. Therefore, it 
thinks that it places a glossodynia as so-called 
non organic chronic pain disease.
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ESC is SSRI of having DAT inhibitory-action 
which is not. Having DA nerve (A10 nerve) 
stimulus operation by the basic experiment 
which used ESC   is reported1),2). However, until 
the present, a reason to the fact isn't made clear.
At this article, it supposed about the logical 
background the mechanism of ESC makes the 
A10 nerve activity rise by inhibiting CRF to the 
non-organic pain in the mouth and face area.
Ⅱ　Methods
　We reported the pharmacotherapy by ESC of 
SSRI to 50 cases of   glossodynia that is a non-
organic-pain3),4). As for the expression of the 
early painkilling effect, it seemed with possibility 
of the restraint, ①5-HT reinforcement of the 
descending pain modulatory system, ②the 
opioid receptor activation with the descending 
pain modulatory system5), ③negative emotion 
block from the amygdala and the hippocampus 
to the nucleus accumbens, ④5-HT1A receptor 
stimulation from the activation of the amygdala, 
⑤DA-phasic activity activation (Fig.1). In this 
time 10 non-organic-pain cases disappeared 
early were considered that the chase result of 
the lightness. Eight cases was disappeared non-
organic-pain in about 2 weeks. But two cases 
of 10 that flared up again continued ESC after 
the symptom disappearance. As the reason 
it considered the action mechanism that the 
decrease a little less than an analgesic effect 
takes from some cases of exacerbation, making 
above ① to ⑤ the basics (Fig.1). 
Ⅲ　Results
　As a result, it was not straight course and 
the reinforcement of the indirect DA isolation 
through the 5HT1A autoreceptor on the 
somatodendritic of the 5-HT nerve was thought 
of.
　It thought that ④ and ⑤ two items were an 
operation with a main restraint mechanism of 
a non-organic-pain. Because exacerbation of a 
non-organic-pain prescribed ESC repeatedly, the 
activation of a 5-HT nerve by the desensitization 
of a 5-HT1A autoreceptor happened. It supposed 
the possibility a little less than that a ①, ② and 
⑤ mechanism brought about the effect decrease.
Ⅳ　Discussion
　The remission or disappearance of the 
chronic pain by  tricyclic antidepressants (TCA) 
have been always accepted in the clinical 
scene. In recent years, new anti-depressants 
of SSRI   or SNRI and so on became clinical 
and available in Japan and the width of the 
choice spread. However, there is little effective 
report to the non-organic pain in Japan to 
SSRI that an adaptation disease does not have 
an effect. We reported because it verified the 
effectivity of ESC of SSRI for the glossodynia 
which is accompanied by an anxiety disorder 
or depressive state.  Moreover, the production 
of effect was added considering about the 
permitted action mechanism from the early 
stage6).
　On the other hand, although ESC is no 
having DAT inhibitory-action, having A10 
nerve stimulus operation by the ESC used 
basic experiment is reported1)2). However, 
Fig.1 　As for the expression of the early painkilling 
effect, it seemed with possibility of 
the restraint ① to ⑤
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until the present, a reason to the fact isn't 
made clear. Moreover, recently the CRF was 
reported to inhibit activity of A10 nerve7). The 
5-HT and DA in a brain decrease in a stress 
and chronic pain8)9). Hereupon the DA of A10 
nerve in a brain decreases, the mechanism of 
the nucleus accumbens, the prefrontal-area and 
the amygdala are decreased too10). The CRF is 
known to prompt for the isolation of a stress 
hormone with the peptide secreted in a brain 
when it receives the various stresses and to 
cause the stress reaction of all characters. Also, 
the CRF secreted in the amygdala and so on 
participates in the occurrence of a negative 
emotion such as the anxiety and fear, too7)11). 
ESC is different from other SSRIs, and we 
know that ESC make a DA increase at the 
ventral tegmental area12) (VTA). We reported 
already the supposition about whether or not 
ESC makes a DA increase4)13). We supposed 
it thought that ④ and ⑤ two items were an 
operation with a main restraint mechanism of 
a non-organic-pain. Because exacerbation of a 
non-organic-pain prescribed ESC repeatedly, the 
activation of a 5-HT nerve by the desensitization 
of a 5-HT1A autoreceptor happened. It supposed 
the possibility a little less than that a ①, ② 
and ⑤ mechanism brought about the effect 
decrease. Therefore amygdala that a functional 
depression declined by RCF is improved with ④ 
and ③(Fig.1). Moreover, DA stimulate by A10 
nerve. After that, DA is undergone metabolic 
change to, and the endogenous opioid  peptide(β
endorphin) is made. When the endogenous 
opioid  peptide(βendorphin)  combine with the 
opioid receptor, non-organic pain is disappeared 
and descending Pain modulation system is 
activated with ①and ②(Fig.1).
Ⅴ　Conclusions
　From the beginning, although ESC is no 
having DAT inhibitory-action, having A10 
nerve stimulus operation by the ESC used 
basic experiment is reported. We supposed the 
mechanism that a DA increases and it supposed 
the mechanism that makes a non-organic pain 
disappear with ① to ⑤(Fig.1). As a result ④ 
and ⑤ two items were an operation with a main 
restraint mechanism of a non-organic-pain. CRF 
secreted in an amygdala and so on participates 
in the occurrence of a negative emotion such 
as the anxiety and fear. ESC is different from 
other SSRIs, and we know that ESC make a DA 
increase at the VTA. We supposed amygdala 
that a functional depression declined by RCF is 
improved with ④ and ③.
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